Search Result

Results for "

antidiabetic agent

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Aldose Reductase (2) AMPK (5) Amylases (4) Amylin Receptor (4) Angiotensin Receptor (1) Antibiotic (3) Apoptosis (5) Bacterial (4) Biochemical Assay Reagents (1) Caspase (2) Dipeptidyl Peptidase (3) Drug Intermediate (2) Endogenous Metabolite (3) Environmental Pollutants (3) Fatty Acid Synthase (FASN) (2) Fungal (1) GCGR (1) GLUT (3) Glycosidase (5) Insulin Receptor (2) Interleukin Related (1) Isotope-Labeled Compounds (5) MAP4K (1) Mitochondrial Metabolism (2) Neprilysin (1) NF-κB (2) p38 MAPK (1) PARP (2) Phosphatase (2) PI3K (1) Potassium Channel (8) PPAR (3) Reactive Oxygen Species (ROS) (3) Reference Standards (11) SGLT (8) TGF-beta/Smad (1) Thyroid Hormone Receptor (1)
By Research Areas:	Cancer (20) Cardiovascular Disease (2) Endocrinology (2) Infection (7) Inflammation/Immunology (7) Metabolic Disease (62) Neurological Disease (2)
Oligonucleotides:	Cholesterol (1)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15516

Sotagliflozin Maximum Cited Publications 13 Publications Verification LX-4211; LP-802034	SGLT	Metabolic Disease
Sotagliflozin (LX-4211) is a potent dual SGLT2/1 inhibitor. Antidiabetic agents.

HY-N4103

Fucosterol 2 Publications Verification	PARP Endogenous Metabolite	Metabolic Disease Cancer
Fucosterol is a sterol isolated from algae, seaweed or diatoms. Fucosterol exhibits various biological activities, including antioxidant, anti-adipogenic, blood cholesterol reducing, anti-diabetic and anti-cancer activities . Fucosterol regulates adipogenesis via inhibition of PPARα and C/EBPα expression and can be used for anti-obesity agents development research .

HY-P0058

Pramlintide	Amylin Receptor	Metabolic Disease Cancer
Pramlintide is a polypeptide analogue of human amylin. Pramlintide, an antidiabetic agent, is antineoplastic in colorectal cancer .

HY-17638

Mizagliflozin 5 Publications Verification DSP-3235 free base; KGA-3235 free base; GSK-1614235 free base	SGLT	Metabolic Disease
Mizagliflozin (DSP-3235 free base) is a potent, orally active and selective SGLT1 inhibitor, with a K_i of 27 nM for human SGLT1. Mizagliflozin displays 303-fold selectivity over SGLT2. Mizagliflozin is used as an antidiabetic agent that can modify postprandial blood glucose excursion. Mizagliflozin also exhibits potential in the amelioration of chronic constipation .

HY-P0058B

Pramlintide acetate	Amylin Receptor	Metabolic Disease Cancer
Pramlintide acetate is a polypeptide analogue of human amylin. Pramlintide acetate, an antidiabetic agent, is antineoplastic in colorectal cancer .

HY-14894

Ipragliflozin 5+ Cited Publications ASP1941	SGLT	Metabolic Disease
Ipragliflozin (ASP1941) is an orally active and selective SGLT2 inhibitor with IC₅₀s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. Antidiabetic agent .

HY-14621

Zingerone Maximum Cited Publications 6 Publications Verification Vanillylacetone; Gingerone	Environmental Pollutants NF-κB	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Zingerone (Vanillylacetone) is a nontoxic methoxyphenol isolated from Zingiber officinale, with potent anti-inflammatory, antidiabetic, antilipolytic, antidiarrhoeic, antispasmodic and anti-tumor properties . Zingerone alleviates oxidative stress and inflammation, down-regulates NF-κB mediated signaling pathways . Zingerone acts as an anti-mitotic agent, and inhibits the growth of neuroblastoma cells . Zingerone can cross the blood-brain barrier (BBB) .

HY-W012634

Benzothiazole	Environmental Pollutants Bacterial	Infection Metabolic Disease Inflammation/Immunology Cancer
Benzothiazole is a natural occurring heterocyclic nuclei. Benzothiazole nucleus possesses a number of biological activities such as anticancer, antimicrobial, antidiabetic, anti-inflammatory, antileishmanial, and antiviral. Furthermore, Benzothiazole nucleus can function as an efficacious β-amyloid imaging agent ^[1][2][3][4].

HY-B0920

Tolazamide 2 Publications Verification U-17835	Potassium Channel	Metabolic Disease Endocrinology
Tolazamide (U-17835) is an orally active sulfonylurea agent that inhibits sulfonylurea receptor 1 (SUR1) linked to the inwardly rectifying potassium channel (IC₅₀ = 4.2 µM in HEK293 cells transfected with the human receptor). Tolazamide has anti-diabetic properties. Tolazamide can lower blood glucose in sulfonylurea class. Tolazamide decreases insulin dose while continuing to maintain adequate metabolic control. Tolazamide is able to improve or normalize hyperglycemia and HbA .

HY-109144

Enavogliflozin DWP-16001	SGLT	Metabolic Disease
Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor .

HY-119244

Gly-Pro-pNA hydrochloride	Dipeptidyl Peptidase	Metabolic Disease
Gly-Pro-pNA hydrochloride is a chromogenic peptide substrate that can be cleaved by the circulating enzyme dipeptidyl peptidase IV (DPP IV). Gly-Pro-pNA hydrochloride is mainly used to detect the activity of aminopeptidases such as DPP IV. Gly-Pro-pNA hydrochloride can be investigated as an experimental antidiabetic agent .

HY-N2486

Desoxyrhaponticin 1 Publications Verification	Fatty Acid Synthase (FASN) Apoptosis	Cancer
Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects.

HY-B0254

Glipizide 2 Publications Verification CP 28720; K 4024	Potassium Channel	Metabolic Disease Cancer
Glipizide (CP 2872; K 4024)?a potent, orally active and sulfonylurea class *anti-diabetic* agent and can be used for type 2?diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium?(K_ATP) channels among β cells of pancreatic islets of Langerhans .

HY-77490

(R)-(-)-1,3-Butanediol	Endogenous Metabolite	Metabolic Disease
(R)-(-)-1,3-Butanediol is the R-enantiomer of 1,3-Butanediol (HY-77490A). (R)-(-)-1,3-Butanediol exhibits anti-diabetic property in rats. (R)-(-)-1,3-Butanediol can be used as flavoring and fragrance agents. (R)-(-)-1,3-Butanediol is used to regulate the metabolism of carbohydrate and lipid. .

HY-B1350A

Fusidic acid sodium salt 2 Publications Verification Sodium fusidate; SQ-16360	Bacterial Antibiotic Interleukin Related	Infection Inflammation/Immunology
Fusidic acid sodium salt is an orally available antibacterial agent that inhibits bacterial protein synthesis by preventing the release of translation elongation factor G (EF-G) from ribosomes. Fusidic acid sodium salt inhibits the inhibitory and activating effects of interleukins IL-1 and IL-6 on glucose-induced insulin production and exhibits antidiabetic effects in a rat model. Fusidic acid sodium salt improves the symptoms of colitis in rats and inhibits the growth of Toxoplasma gondii and Listeria monocytogenes EGD in vitro, but not in mice .

HY-B2099A

Buformin hydrochloride 3 Publications Verification 1-Butylbiguanide hydrochloride	AMPK	Cancer
Buformin hydrochloride (1-Butylbiguanide hydrochloride), a potent AMPK activator, acts as an orally active biguanide **antidiabetic agent*. Buformin hydrochloride decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin hydrochloride also has anti*-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al) .

HY-125012

MAP4K4-IN-3 1 Publications Verification	MAP4K	Metabolic Disease
MAP4K4-IN-3 (Compound 17) is a potent and selective MAP4K4 inhibitor with an IC₅₀ of 14.9 nM in kinase assay, an IC₅₀ of 470 nM in cell assay. Antidiabetic agent .

HY-W075770

Nickel(II) oxide Nickel monoxide	Environmental Pollutants Apoptosis Reactive Oxygen Species (ROS) Caspase TGF-beta/Smad p38 MAPK Akt PI3K	Infection Metabolic Disease Cancer
Nickel(II) oxide (nickel monoxide) is a chemical warfare agent that can enter the body through the respiratory tract and other routes, distributing to organs such as the lungs and testes. The nanoparticle form of nickel(II) oxide (NiO NPs) exhibits antibacterial, anti-leishmanial, anti-diabetic, and anti-cancer activities. NiO NPs can be activated by ultraviolet and visible light, generating reactive oxygen species (ROS). Nickel(II) oxide induces oxidative stress by generating reactive oxygen species, activating the TGF-β1-mediated MAPK and PI3K/AKT pathways, disrupting the MMPs/TIMPs balance, and upregulating the expression of inflammatory factors (IL-1β, IL-6) and apoptosis-related molecules (Bax, caspase-3, p53), while inhibiting the activity of the anti-apoptotic molecule Bcl-2. Nickel(II) oxide induces cytotoxicity, promotes fibrosis, triggers inflammatory responses, and causes apoptosis. Nickel(II) oxide can be applied in research on the safety assessment of nanomaterials, such as in the context of pulmonary fibrosis and reproductive system toxicity .

HY-163853

Antidiabetic agent 6	GLUT Akt	Metabolic Disease
Antidiabetic agent 6 (Compound 19) is an antidiabetic Agent. Antidiabetic agent 6 stimulates GLUT4 translocation by activation of the PI3K/AKT-dependent signaling pathway. Antidiabetic agent 6 reduces blood glucose levels in Streptozotocin (HY-13753)-induced diabetic rats .

HY-130289

(±)4-HDHA 4-Hydroxy docosahexaenoic acid; (±)4-HDoHE	PPAR	Metabolic Disease Inflammation/Immunology
(±)4-HDHA (4-Hydroxy docosahexaenoic acid) is an autoxidation product of Docosahexaenoic acid (HY-B2167) (DHA). (±)4-HDHA is a PPARγ agonist, antidiabetic and anti-inflammatory agent .

HY-134769

OPC-163493	Mitochondrial Metabolism Reactive Oxygen Species (ROS)	Cardiovascular Disease Metabolic Disease
OPC-163493 is an orally active and liver-targeted mitochondrial uncoupling agent. OPC-163493 reduces the production of mitochondrial Δψ and ROS. OPC-163493 has anti-diabetic and lipid-lowering effects. In addition, OPC-163493 has a protective effect on cardiovascular disease .

HY-N2486R

Desoxyrhaponticin (Standard)	Reference Standards Fatty Acid Synthase (FASN) Apoptosis	Cancer
Desoxyrhaponticin (Standard) is the analytical standard of Desoxyrhaponticin. This product is intended for research and analytical applications. Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects .

HY-B0254S

Glipizide-d11	Isotope-Labeled Compounds Potassium Channel	Metabolic Disease
Glipizide-d₁₁ is the deuterium labeled Glipizide. Glipizide (CP 2872; K 4024)?a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2?diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium?(KATP) channels among β cells of pancreatic islets of Langerhans .

HY-B0254R

Glipizide (Standard) CP 28720 (Standard); K 4024 (Standard)	Reference Standards Potassium Channel	Metabolic Disease
Glipizide (Standard) is the analytical standard of Glipizide. This product is intended for research and analytical applications. Glipizide (CP 2872; K 4024) a potent, orally active and sulfonylurea class *anti-diabetic* agent and can be used for type 2 diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium (K_ATP) channels among β cells of pancreatic islets of Langerhans .

HY-B2099

Buformin 1-Butylbiguanide	AMPK	Metabolic Disease Cancer
Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide **antidiabetic agent*. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti*-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al) .

HY-W041324

Glimepiride sulfonamide	Drug Intermediate	Infection
Glimepiride sulfonamide is a intermediate, and can be used to synthesize Glimepiride (HY-B0104) (antidiabetic agent) .

HY-120401

Glybuzole Desaglybuzole	Insulin Receptor GCGR	Metabolic Disease
Glybuzole (Desaglybuzole) is an orally active hypoglycaemic agent that has antidiabetic effect .

HY-17451

Glibornuride	Potassium Channel	Metabolic Disease
Glibornuride is a blocker of ATP-sensitive K ⁺ channels (K_ATP channel) with a pK_i of 5.75 . Antidiabetic agent .

HY-117167

KB-141	Thyroid Hormone Receptor	Cancer
KB-141 is a potent and selective TRβ agonist. The IC₅₀ values are 23.9 nM and 3.3 nM for binding affinities from displacement of T3 from hTRα1 and hTRβ1, respectively. KB-141 has anti-obesity, anti-diabetic, and lipid-lowering effects?and can be used as an *anti-cholesteremic* agent in vivo .

HY-N4103R

Fucosterol (Standard)	Reference Standards PARP Endogenous Metabolite	Metabolic Disease Cancer
Fucosterol (Standard) is the analytical standard of Fucosterol. This product is intended for research and analytical applications. Fucosterol is a sterol isolated from algae, seaweed or diatoms. Fucosterol exhibits various biological activities, including antioxidant, anti-adipogenic, blood cholesterol reducing, anti-diabetic and anti-cancer activities . Fucosterol regulates adipogenesis via inhibition of PPARα and C/EBPα expression and can be used for anti-obesity agents development research .

HY-161429

Antidiabetic agent 5	Amylases Glycosidase	Metabolic Disease
Antidiabetic agent 5 (compound S1) is a antidiabetic agent. Antidiabetic agent 5 inhibits the activity of α-glucosidase and α-amylase with IC₅₀ values of 3.91，8.89 μM，respectively. Antidiabetic agent 5 decreases sugar levels. Antidiabetic agent 5 has the potential for the research of type-II diabetes .

HY-170943

Antidiabetic agent 7	AMPK GLUT	Metabolic Disease
Antidiabetic agent 7 (Compound 5m) is hyperglycemic inhibitor. Antidiabetic agent 7 exhibits promising potency to stimulate GLUT4 translocation in skeletal muscle cells via activating AMPK-dependent pathway. Antidiabetic agent 7 reduces blood glucose levels. Antidiabetic agent 7 shows favorable pharmacokinetic properties. Antidiabetic agent 7 is potential to be used for anti-hyperglycemic research .

HY-172904

Antidiabetic agent 15	Angiotensin Receptor Neprilysin	Cardiovascular Disease Neurological Disease Metabolic Disease
Antidiabetic agent 15 (compound 1B15) is a AT1R and NEP dual inhibitor. Antidiabetic agent 15 reduces the oxidative stress and restores the mitochondrial membrane potential .

HY-155961

Antidiabetic agent 2	Dipeptidyl Peptidase Phosphatase Amylases Glycosidase	Metabolic Disease
Antidiabetic agent 2 (Compound 56) is a glucose-uptake promoter. Antidiabetic agent 2 inhibits DPP-4, PTP-1B, α-amylase, and α-glucosidase with IC₅₀s of 0.036, 0.042, 0.241, 0.185 μM. Antidiabetic agent 2 decreases blood glucose levels .

HY-P0058A

Pramlintide TFA	Amylin Receptor	Metabolic Disease Cancer
Pramlintide TFA is a polypeptide analogue of human amylin. Pramlintide TFA, an antidiabetic agent, is antineoplastic in colorectal cancer .

HY-15516R

Sotagliflozin (Standard) LX-4211 (Standard); LP-802034 (Standard)	SGLT Reference Standards	Metabolic Disease
Sotagliflozin (Standard) is the analytical standard of Sotagliflozin. This product is intended for research and analytical applications. Sotagliflozin (LX-4211) is a potent dual SGLT2/1 inhibitor. Antidiabetic agents.

HY-174145

GLUT4 activator 3	GLUT	Metabolic Disease
GLUT4 activator 3 (Compound 13a) is an antidiabetic agent targeting GLUT4 translocation in skeletal muscle. GLUT4 activator 3 can promote the translocation of glucose transporter 4 (GLUT4) in skeletal muscle cells. GLUT4 activator 3 reduces blood glucose in STZ-induced diabetic rats .

HY-N6883

6-Methoxytricin	Aldose Reductase	Metabolic Disease
6-Methoxytricin (Compound 6) is an flavonoid isolated from Artemisia iwayomogi. 6-Methoxytricin (Compound 6) is an inhibitor on aldose reductase (AR) and advanced glycation endproduct (AGE) formation activities with IC₅₀ values of 30.29 μM and 134.88 μM, respectively. 6-Methoxytricin (Compound 6) has potential as an anti-diabetic complications agent .

HY-15383

Glyparamide	Biochemical Assay Reagents	Metabolic Disease
Glyparamide is an orally active hypoglycemic compound that serves as an auxiliary active ingredient in anti-diabetic agents. Glyparamide can be used in combination with preparations of Rhodamnia cinerea extract and is applicable to the study of hyperglycemia-related disorders-specifically those involving carbohydrate metabolism disturbances-including Type 2 diabetes, metabolic syndrome, and postprandial hyperglycemia. Other notable hypoglycemic agents of significant interest include: Tolbutamide (HY-B0401), Chlorpropamide (HY-B1429), Metformin (HY-B0627), and Glimepiride (HY-B0104) .

HY-B2099AR

Buformin hydrochloride (Standard) 1-Butylbiguanide hydrochloride (Standard)	AMPK Reference Standards	Cancer
Buformin (hydrochloride) (Standard) is the analytical standard of Buformin (hydrochloride). This product is intended for research and analytical applications. Buformin hydrochloride (1-Butylbiguanide hydrochloride), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin hydrochloride decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin hydrochloride also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al) .

HY-121731

Nimbocinone	Others	Metabolic Disease
Nimbocinone, isolated from Azadirachta indica, exhibits antidiabetogenic activity .

HY-181683

Antidiabetic agent 8		Metabolic Disease
Antidiabetic agent 8 is an orally active multi-target inhibitor, with IC₅₀ values of 9.79, 6.36 and 19.08 μM against α-glucosidase, α-amylase and PTP1B, respectively. Antidiabetic agent 8 reduces postprandial blood glucose elevation. Antidiabetic agent 8 can be used in the research of type 2 diabetes .

HY-101758

BM-131246	Insulin Receptor	Metabolic Disease
BM-131246 is an oral antidiabetic agent.

HY-172786

Caspase-3-IN-3	Caspase Apoptosis	Metabolic Disease
Caspase-3-IN-3 (compound 7) is a caspase 3 inhibitor. Caspase-3-IN-3 increases cellular ATP levels, inhibits caspase-3 activity, decreases nitrite production, suppresses cytokine-induced apoptosis, and restores Glucose (HY-B0389)-stimulated insulin secretion .

HY-168621

DPP-4-IN-13	Dipeptidyl Peptidase	Metabolic Disease
DPP-4-IN-13 (compound 9i) is a competitive DPP4 inhibitor with the IC₅₀ of 9.25 μM and can be used for study of type 2 diabetes .

HY-131051

Antimicrobial agent-41	Reactive Oxygen Species (ROS) Bacterial Fungal	Infection
Antimicrobial agent-41 (Compound 19) is a thiazolidinedione derivative. Antimicrobial agent-41 exhibits excellent antioxidant activity (IC₅₀ = 27.66 μg/mL). Antimicrobial agent-41 also exhibits antidiabetic activity (IC₅₀ = 40.01 μg/mL). Antimicrobial agent-41 has antimicrobial activity again both bacterial and fungi .

HY-131504A

Valienamine	Glycosidase	Metabolic Disease
Valienamine is the alpha-glucosidase inhibitor. Valienamine is the key functional component of many natural glycosidase inhibitors including the crop protectant validamycin A and the antidiabetic agent acarbose .

HY-B1114S

Gliquidone-d6 AR-DF 26-d₆	Isotope-Labeled Compounds	Metabolic Disease
Gliquidone-d₆ is deuterium labeled Gliquidone. Gliquidone (AR-DF 26) is an anti-diabetic agent in the sulfonylurea class, used in the treatment of diabetes mellitus type 2.

HY-126198A

Linogliride fumarate McN-3935 fumarate	Antibiotic	Metabolic Disease
Linogliride (MCN-3935) fumarate is an antidiabetic agent. Linogliride fumarate (100 μM) does not affect insulin secretion in the absence of glucose, but has a significant insulinotropic effect in the presence of 5.5 mM glucose .

HY-126198

Linogliride McN-3935	Antibiotic	Metabolic Disease
Linogliride (MCN-3935) is an antidiabetic agent. Linogliride (100 μM) does not affect insulin secretion in the absence of glucose, but has a significant insulinotropic effect in the presence of 5.5 mM glucose .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N4103

Fucosterol 2 Publications Verification	other families Classification of Application Fields Metabolic Disease Plants Endogenous metabolite Disease Research Fields Steroids Source Classification	PARP Endogenous Metabolite
Fucosterol is a sterol isolated from algae, seaweed or diatoms. Fucosterol exhibits various biological activities, including antioxidant, anti-adipogenic, blood cholesterol reducing, anti-diabetic and anti-cancer activities . Fucosterol regulates adipogenesis via inhibition of PPARα and C/EBPα expression and can be used for anti-obesity agents development research .

HY-14621

Zingerone Maximum Cited Publications 6 Publications Verification Vanillylacetone; Gingerone	Zingiber officinale Roscoe Structural Classification Monophenols Classification of Application Fields Ketones, Aldehydes, Acids Phenols Metabolic Disease Plants Inflammation/Immunology Disease Research Fields Source Classification Zingiberaceae	Environmental Pollutants NF-κB
Zingerone (Vanillylacetone) is a nontoxic methoxyphenol isolated from Zingiber officinale, with potent anti-inflammatory, antidiabetic, antilipolytic, antidiarrhoeic, antispasmodic and anti-tumor properties . Zingerone alleviates oxidative stress and inflammation, down-regulates NF-κB mediated signaling pathways . Zingerone acts as an anti-mitotic agent, and inhibits the growth of neuroblastoma cells . Zingerone can cross the blood-brain barrier (BBB) .

HY-W012634

Benzothiazole	Source Classification	Environmental Pollutants Bacterial
Benzothiazole is a natural occurring heterocyclic nuclei. Benzothiazole nucleus possesses a number of biological activities such as anticancer, antimicrobial, antidiabetic, anti-inflammatory, antileishmanial, and antiviral. Furthermore, Benzothiazole nucleus can function as an efficacious β-amyloid imaging agent ^[1][2][3][4].

HY-N2486

Desoxyrhaponticin 1 Publications Verification	Monophenols Stilbenes Classification of Application Fields Polygonaceae Rheum rhabarbarum Linnaeus Phenols Plants Rheum tanguticum Disease Research Fields Source Classification Cancer	Fatty Acid Synthase (FASN) Apoptosis
Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects.

HY-77490

(R)-(-)-1,3-Butanediol	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
(R)-(-)-1,3-Butanediol is the R-enantiomer of 1,3-Butanediol (HY-77490A). (R)-(-)-1,3-Butanediol exhibits anti-diabetic property in rats. (R)-(-)-1,3-Butanediol can be used as flavoring and fragrance agents. (R)-(-)-1,3-Butanediol is used to regulate the metabolism of carbohydrate and lipid. .

HY-B1350A

Fusidic acid sodium salt 2 Publications Verification Sodium fusidate; SQ-16360	Infection Triterpenes Microorganisms Classification of Application Fields Terpenoids Disease Research Fields Source Classification Cancer	Bacterial Antibiotic Interleukin Related
Fusidic acid sodium salt is an orally available antibacterial agent that inhibits bacterial protein synthesis by preventing the release of translation elongation factor G (EF-G) from ribosomes. Fusidic acid sodium salt inhibits the inhibitory and activating effects of interleukins IL-1 and IL-6 on glucose-induced insulin production and exhibits antidiabetic effects in a rat model. Fusidic acid sodium salt improves the symptoms of colitis in rats and inhibits the growth of Toxoplasma gondii and Listeria monocytogenes EGD in vitro, but not in mice .

HY-N2486R

Desoxyrhaponticin (Standard)	Structural Classification Monophenols Stilbenes Polygonaceae Rheum rhabarbarum Linnaeus Phenols Plants Rheum tanguticum Source Classification	Reference Standards Fatty Acid Synthase (FASN) Apoptosis
Desoxyrhaponticin (Standard) is the analytical standard of Desoxyrhaponticin. This product is intended for research and analytical applications. Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects .

HY-N4103R

Fucosterol (Standard)	other families Classification of Application Fields Metabolic Disease Plants Endogenous metabolite Disease Research Fields Steroids Source Classification	Reference Standards PARP Endogenous Metabolite
Fucosterol (Standard) is the analytical standard of Fucosterol. This product is intended for research and analytical applications. Fucosterol is a sterol isolated from algae, seaweed or diatoms. Fucosterol exhibits various biological activities, including antioxidant, anti-adipogenic, blood cholesterol reducing, anti-diabetic and anti-cancer activities . Fucosterol regulates adipogenesis via inhibition of PPARα and C/EBPα expression and can be used for anti-obesity agents development research .

HY-N6883

6-Methoxytricin	Flavonoids other families Classification of Application Fields Flavones Phenols Polyphenols Metabolic Disease Plants Disease Research Fields Source Classification	Aldose Reductase
6-Methoxytricin (Compound 6) is an flavonoid isolated from Artemisia iwayomogi. 6-Methoxytricin (Compound 6) is an inhibitor on aldose reductase (AR) and advanced glycation endproduct (AGE) formation activities with IC₅₀ values of 30.29 μM and 134.88 μM, respectively. 6-Methoxytricin (Compound 6) has potential as an anti-diabetic complications agent .

HY-121731

Nimbocinone	Triterpenes Terpenoids Plants Azadirachta indica A. Juss. Meliaceae Source Classification	Others
Nimbocinone, isolated from Azadirachta indica, exhibits antidiabetogenic activity .

HY-N11844

Quercetin 3-(6″-caffeoylsophoroside)	Natural Products Cardamine hirsuta L. Plants Brassicaceae Source Classification	Amylases
Quercetin 3-(6″-caffeoylsophoroside) is an orally active α-amylase inhibitor, with an IC₅₀ of 73.66 μg/mL. Quercetin 3-(6″-caffeoylsophoroside) presents in thehydro-methanolic extract of Cardamine hirsuta Linn. Quercetin 3-(6″-caffeoylsophoroside) shows the antidiabetic activities by oxidative stress reduction and α-amylase inhibition. Quercetin 3-(6″-caffeoylsophoroside) can be used for diabetes mellitus research .

HY-163899

(+)-Crinatusin A1	Other Monoterpenes Terpenoids Myrtaceae Plants Syzygium nervosum Candolle Source Classification	Phosphatase
(+)-Crinatusin A1 (Compound (+)- 4) is a chalcone-monoterpene hybrid, which can be isolated from Cleistocalyx operculatus. (+)-Crinatusin A1 is an inhibitor for protein tyrosine phosphatase 1B (PTP1B) with IC₅₀ of 0.9 μM. (+)-Crinatusin A1 exhibits potential as an antidiabetic agent .

HY-W012634R

Benzothiazole (Standard)	Microorganisms Source Classification	Reference Standards Bacterial
Benzothiazole (Standard) is the analytical standard of Benzothiazole. This product is intended for research and analytical applications. Benzothiazole is a natural occurring heterocyclic nuclei. Benzothiazole nucleus possesses a number of biological activities such as anticancer, antimicrobial, antidiabetic, anti-inflammatory, antileishmanial, and antiviral. Furthermore, Benzothiazole nucleus can function as an efficacious β-amyloid imaging agent .

HY-14621R

Zingerone (Standard) Vanillylacetone (Standard); Gingerone (Standard)	Zingiber officinale Roscoe Structural Classification Monophenols Microorganisms Ketones, Aldehydes, Acids Phenols Plants Source Classification Zingiberaceae	Reference Standards NF-κB
Zingerone (Standard) is the analytical standard of Zingerone. This product is intended for research and analytical applications. Zingerone (Vanillylacetone) is a nontoxic methoxyphenol isolated from Zingiber officinale, with potent anti-inflammatory, antidiabetic, antilipolytic, antidiarrhoeic, antispasmodic and anti-tumor properties . Zingerone alleviates oxidative stress and inflammation, down-regulates NF-κB mediated signaling pathways . Zingerone acts as an anti-mitotic agent, and inhibits the growth of neuroblastoma cells .

Cat. No.	Product Name	Chemical Structure

HY-B0254S

Glipizide-d11
Glipizide-d₁₁ is the deuterium labeled Glipizide. Glipizide (CP 2872; K 4024)?a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2?diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium?(KATP) channels among β cells of pancreatic islets of Langerhans .

HY-B1114S

Gliquidone-d6
Gliquidone-d₆ is deuterium labeled Gliquidone. Gliquidone (AR-DF 26) is an anti-diabetic agent in the sulfonylurea class, used in the treatment of diabetes mellitus type 2.

HY-P0058S

Pramlintide-(Ala-13C3,15N)
Pramlintide-(Ala- ¹³C₃, ¹⁵N) is the ¹³C- and ¹⁵N-labeled Pramlintide. Pramlintide is a polypeptide analogue of human amylin. Pramlintide, an antidiabetic agent, is antineoplastic in colorectal cancer .

HY-B2099S

Buformin-d9 hydrochloride
Buformin-d₉ (hydrochloride) is the deuterium labeled Buformin. Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al) .

HY-14894S2

Pragliflozin-13C6
Pragliflozin- ¹³C₆ (ASP1941- ¹³C₆) is ¹³C labeled Ipragliflozin. Ipragliflozin (ASP1941) is an orally active and selective SGLT2 inhibitor with IC₅₀s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. Antidiabetic agent .

Cat. No.	Product Name		Classification

HY-N4103

Fucosterol 2 Publications Verification		Cholesterol
Fucosterol is a sterol isolated from algae, seaweed or diatoms. Fucosterol exhibits various biological activities, including antioxidant, anti-adipogenic, blood cholesterol reducing, anti-diabetic and anti-cancer activities . Fucosterol regulates adipogenesis via inhibition of PPARα and C/EBPα expression and can be used for anti-obesity agents development research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

antidiabetic agent

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products